Wan-Ching Yen

Medicine · Health Sciences

19h-index2.3kcitations101works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(25), Retinoids in leukemia and cellular processes(17), Cancer Treatment and Pharmacology(15), Colorectal Cancer Treatments and Studies(14), Cancer-related gene regulation(13)

Publications101 total

Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix
Journal of Medicinal Chemistry·2025· 1 citedOpen Access
Investigational New Drug-enabling studies to use genetically modified mesenchymal stromal cells in patients with critical limb ischemia
Stem Cells Translational Medicine·2025· 4 citedOpen Access
Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Abstract 1809: Discovery of novel AXL and MER inhibitors as potential anticancer and immunomodulatory drugs
Cancer Research·2024
Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Data from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Supplementary Tables 1-5, Supplementary Methods and Materials from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Data from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Data from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Data from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Supplementary Figures 1-5 from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Supplementary Figures 1-5 from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Supplementary Tables 1-5, Supplementary Methods and Materials from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
2023Open Access
Figures S1-S7 from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Data from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
Supplementary Table 1 from Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification
2023Open Access
Supplementary Figure 3 from Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic <i>KRAS</i> Mutations
2023Open Access
Supplementary Figure 4 from Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic <i>KRAS</i> Mutations
2023Open Access
Tables S1-S3 from Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
2023Open Access
page 1 of 6Next →

Frequent Co-authors

John Lewicki(26), Marcus Fischer(25), Austin Gurney(24), Timothy Hoey(22), Ann M. Kapoun(21), Belinda Cancilla(14), Pete Yeung(12), Jennifer Cain(9), Fiore Cattaruzza(9), Gilbert O’Young(9), William W. Lamph(9), A. Negro‐Vilar(8), Fumiko Axelrod(7), Cécile Chartier(6), Jalpa Shah(6), Reid P. Bissonnette(6), Aaron K. Sato(5), Patricia Tooker(5), Thomas Hermann(5), Alayne Brunner(5)